Loading...
OTCM
GNCAQ
Market cap0kUSD
Mar 11, Last price  
0.00USD
1D
-99.00%
1Q
0.00%
IPO
-99.00%
Name

Genocea Biosciences Inc

Chart & Performance

D1W1MN
P/E
P/S
0.00
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
26.62%
Revenues
2m
+20.75%
1,820,0001,977,000731,000308,000670,000235,0000001,359,0001,641,000
Net income
-15m
L-64.73%
-14,685,000-13,367,000-20,806,000-35,296,000-42,483,000-49,573,000-56,710,000-27,811,000-38,950,000-43,714,000-15,420,000
CFO
-45m
L+8.93%
-13,488,000-12,681,000-19,873,000-27,604,000-38,356,000-41,835,000-47,599,000-41,235,000-37,734,000-41,651,000-45,370,000

Profile

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
IPO date
Feb 05, 2014
Employees
74
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT